In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $17.43. The company’s shares closed yesterday at $15.91.
Goonewardene covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Genmab, and Compugen. According to TipRanks, Goonewardene has an average return of 9.7% and a 39.64% success rate on recommended stocks.
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.20, implying a 58.39% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $18.33 and a one-year low of $3.21. Currently, Iovance Biotherapeutics has an average volume of 10.46M.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IOVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Iovance Biotherapeutics (IOVA) Company Description:
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients’ tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Read More on IOVA:
- Iovance Biotherapeutics price target raised to $22 from $18 at Barclays
- Iovance Biotherapeutics reports Q4 EPS (45c), consensus (43c)
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- Iovance Biotherapeutics call volume above normal and directionally bullish
- IOVA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
